| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
Andolast (CR 2039) (intravenous or intramuscular injection) reduces passive cutaneous anaphylaxis (PCA) in rats with an ED50 of 0.1 mg/kg[1]. CR 2039 (10-100 mg/kg; intravenously or intramuscularly) reduces alterations in microvascular permeability in a sensitized guinea pig model of allergic conjunctivitis [1]. CR 2039 (0-1000 μM; intravenous injection) dose-dependently inhibits guinea pig lung cAMP-phosphodiesterase with an IC50 value of 50 μM [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male Hartley guinea pig (300-500 g) [1]
Doses: 10-100 mg/kg Route of Administration: intramuscularinjection; IV Experimental Results: Demonstrated dependence on lgE induced by aerosolized antigen in anesthetized guinea pigs Dose-related significant protective effect against bronchial allergic reactions. Dose-dependently delays the onset of aerosolized antigen-induced bronchoconstriction. |
| References |
[1]. Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992;229(1):45-53.
[2]. Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998;8(3):233-238. |
| Molecular Formula |
C15H11N9O
|
|---|---|
| Molecular Weight |
333.30754
|
| CAS # |
132640-22-3
|
| Related CAS # |
Andolast;143330-46-5
|
| SMILES |
N1=C(C2C=CC(C(NC3C=CC(C4=NNN=N4)=CC=3)=O)=CC=2)N=NN1
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~150.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0002 mL | 15.0011 mL | 30.0021 mL | |
| 5 mM | 0.6000 mL | 3.0002 mL | 6.0004 mL | |
| 10 mM | 0.3000 mL | 1.5001 mL | 3.0002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
